UB Paderborn / Katalog / Suche / in CDI

1 – 12 von 12

Sortiert nach

Metabolism and excretion of tolcapone, a novel inhibitor of catechol‐O‐methyltransferase

British journal of clinical pharmacology, 1999-10, Vol.48 (4), p.513-520

1999

Volltextzugriff (PDF)

The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations

European neurology, 1997-01, Vol.38 (1), p.59

1997

Volltextzugriff (PDF)

Lack of Interaction between Tolcapone and Tolbutamide in Healthy Volunteers

Journal of clinical pharmacology, 2000-05, Vol.40 (5), p.544-551

2000

Volltextzugriff (PDF)

Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients

Clinical pharmacokinetics, 1999-07, Vol.37 (1), p.75-86

1999

Volltextzugriff (PDF)

The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation

Journal of neurology, 1998-04, Vol.245 (4), p.223-230

1998

Volltextzugriff (PDF)

Integrated pharmacokinetics and pharmacodynamics of the novel catechol‐O‐methyltransferase inhibitor tolcapone during first administration to humans

Clinical pharmacology and therapeutics, 1995-05, Vol.57 (5), p.508-517

1995

Volltextzugriff (PDF)

Population pharmacokinetics of levodopa in patients with Parkinson's disease treated with tolcapone

Clinical pharmacology and therapeutics, 2000-06, Vol.67 (6), p.610-620

2000

Volltextzugriff (PDF)

Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly

Clinical pharmacology and therapeutics, 1997-09, Vol.62 (3), p.300-310

1997

Volltextzugriff (PDF)

Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies

British journal of clinical pharmacology, 2000-01, Vol.49 (1), p.39-48

2000

Volltextzugriff (PDF)

The effect of tolcapone on the pharmacokinetics of benserazide

European journal of neurology, 1999-03, Vol.6 (2), p.211-219

1999

Volltextzugriff (PDF)

Clinical, pharmacokinetic, and pharmacodynamic effects of tolcapone withdrawal in levodopa-treated patients with parkinsonism

Clinical neuropharmacology, 2000-03, Vol.23 (2), p.98-105

2000

Volltextzugriff (PDF)

Switch in treatment from tricyclic antidepressants to moclobemide : a new generation monoamine oxidase inhibitor

Journal of clinical psychopharmacology, 1995-02, Vol.15 (1), p.41-48

1995

Volltextzugriff (PDF)

1 – 12 von 12

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(12)
Mit Volltextzugriff
(9)

Publikationsform

Artikel
(12)

Sprache

Englisch
(12)
Japanisch
(5)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Metabolism and excretion of tolcapone, a novel inhibitor of catechol‐O‐methyltransferase

The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations

Lack of Interaction between Tolcapone and Tolbutamide in Healthy Volunteers

Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients

The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation

Integrated pharmacokinetics and pharmacodynamics of the novel catechol‐O‐methyltransferase inhibitor tolcapone during first administration to humans

Population pharmacokinetics of levodopa in patients with Parkinson's disease treated with tolcapone

Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly

Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies

The effect of tolcapone on the pharmacokinetics of benserazide

Clinical, pharmacokinetic, and pharmacodynamic effects of tolcapone withdrawal in levodopa-treated patients with parkinsonism

Switch in treatment from tricyclic antidepressants to moclobemide : a new generation monoamine oxidase inhibitor

Suchergebnisse filtern